Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Innate Pharma S.A. Sponsored ADR (IPHA : NSDQ)

• Company Description    Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company's commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France. Number of Employees: 181

• Price / Volume Information    Yesterday's Closing Price: $1.82 Daily Weekly Monthly 20 Day Moving Average: 11,725 shares Shares Outstanding: 92.18 (millions) Market Capitalization: $167.76 (millions) Beta: 0.21 52 Week High: $3.51 52 Week Low: $1.29 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.95% -18.46% 12 Week 0.25% -12.16% Year To Date -1.09% -6.58%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 117 AVENUE DE LUMINY BP 30191 - MARSEILLE,I0 13009 FRA ph: 33-4-30-30-30-30 fax: - investors@innate-pharma.fr http://www.innate-pharma.com

• General Corporate Information    Officers Mondher Mahjoubi - Chief Executive Officer and Chairman Herve Brailly - Chairman Irina Staatz-Granzer - Vice Chairman Frederic Lombard - Chief Financial Officer Yannis Morel - Executive Vice president Peer Information Innate Pharma S.A. Sponsored ADR (CORR.) Innate Pharma S.A. Sponsored ADR (RSPI) Innate Pharma S.A. Sponsored ADR (CGXP) Innate Pharma S.A. Sponsored ADR (BGEN) Innate Pharma S.A. Sponsored ADR (GTBP) Innate Pharma S.A. Sponsored ADR (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45781K204 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: 05/13/25 Share - Related Items Shares Outstanding: 92.18 Most Recent Split Date: (:1) Beta: 0.21 Market Capitalization: $167.76 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.82 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 15.96 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 2.60 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 2.60 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -245.87 Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - 0.11 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 2.52 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 71.61

Powered by Zacks Investment Research ©